Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.

Journal of thrombosis and haemostasis : JTH - 1 Jan 2007

Colaizzo D, Amitrano L, Tiscia G L, Scenna G, Grandone E, Guardascione M A, Brancaccio V, Margaglione M

Abstract excerpt

BACKGROUND: Myeloproliferative disorders (MPDs) represent a risk factor for thrombosis in the portal, mesenteric, and hepatic districts. OBJECTIVE: We aimed to assess whether the Janus kinase 2 (JAK2) V617F mutation, an acquired mutation that occurs in MPD patients, is a risk factor for portal and mesenteric venous thrombosis (PMVT) independently of the presence of overt MPDs. PATIENTS AND METHODS: The medical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Italy
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Share to Phenylalanine

Share to Portal Vein

Share to Valine

Share to Venous Thrombosis

Share to Von Hippel-Lindau Tumor Suppressor Protein

Source

Identifiers

PMID: 17059429
DOI: 10.1111/j.1538-7836.2006.02277.x

Genes

JAK2
VHL

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.PMID 17059429Read ↗

The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.Semantic proximity Read ↗

Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.Semantic proximity Read ↗

Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.Semantic proximity Read ↗

JAK2 mutation: an aid in the diagnosis of occult myeloproliferative neoplasms in patients with major intraabdominal vein thrombosis and normal blood counts.Semantic proximity Read ↗

JAK2 mutation-related disease and thrombosis.Semantic proximity Read ↗

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.Semantic proximity Read ↗

Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation.Semantic proximity Read ↗

Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.Semantic proximity Read ↗

[Thrombosis in myeloproliferative neoplasms].Semantic proximity Read ↗

JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders.Semantic proximity Read ↗

Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.Semantic proximity Read ↗

The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.